Mir A. Hashim
Papers
8
Total Citations
110
H-Index
3
About
Mir A. Hashim is a pioneering researcher in the field of oral biotherapeutic delivery, whose work is transforming how patients receive treatments that traditionally require injections. His primary research focuses on developing an orally ingestible robotic pill that can safely and effectively deliver large-molecule drugs—such as antibodies, peptides, and hormones—directly through the intestinal wall, bypassing the digestive system’s destructive environment. Hashim’s most influential work, a 2021 study with 94 citations, demonstrated the safety, tolerability, and performance of this robotic pill in healthy subjects, marking a critical step toward replacing painful, chronic injections. His subsequent phase 1 clinical trials have shown that the pill can deliver teriparatide for osteoporosis and a GLP-1 agonist for diabetes with high bioavailability—comparable to subcutaneous injections. These achievements, including successful delivery of an ustekinumab biosimilar and follicle-stimulating hormone, address a long-standing challenge in medicine: improving patient compliance for chronic conditions like osteoporosis, diabetes, and autoimmune diseases. Hashim’s research not only promises to eliminate the pain and inconvenience of injections but also opens the door to more effective, patient-friendly therapies for millions worldwide.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8